Cencora (COR) Q4 FY2026 Earnings Call: Guidance and Outlook
Formal guidance covers fiscal year 2027, featuring consolidated financial targets alongside specific metrics for the newly established operating segments.
About Cencora. Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. S.
Adjusted diluted EPS in the first quarter is expected to be approximately $4.55.
Annual guidance
Adjusted Diluted EPS
$19.40 to $19.75, reflecting headline growth of 8% to 10%.
Consolidated Revenue Growth
3% to 5%.
Operating Income Growth
4% to 6%.
Capital Expenditures
Approximately $1 billion.
Adjusted Free Cash Flow
Approximately $3.5 billion.
Outlook
Specialty market demand
Specialty biologics account for more than half of U.S. pharmaceutical spending, with over 100 new products expected to launch through 2030.
Specialty distribution revenue
Specialty distribution revenue is expected to reach approximately $100 billion in fiscal 2027.
Segment long-term targets
Pharmaceutical Distribution and Services operating income is expected to grow in the mid-single digits long-term, while Specialty Pharmaceutical and Provider Services operating income is expected to grow in the mid-teens.
Share repurchases
Management expects an additional $1.25 billion in share repurchases during fiscal 2027.
Dombey's summary of the Cencora Q4 FY2026 earnings call held Nov 4, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
